BEQALZI Drug Patent Profile

Which patents cover Beqalzi, and what generic alternatives are available?

Beqalzi is a drug marketed by Beone Medicines Usa and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-two countries.

The generic ingredient in BEQALZI is sonrotoclax. Additional details are available on the sonrotoclax profile page.

DrugPatentWatch^® Generic Entry Outlook for Beqalzi

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 29, 2039. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for BEQALZI

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for BEQALZI

BEQALZI is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Beone Medicines Usa	BEQALZI	sonrotoclax	TABLET;ORAL	220711-001	May 13, 2026		RX	Yes	No			Y	Y
Beone Medicines Usa	BEQALZI	sonrotoclax	TABLET;ORAL	220711-004	May 13, 2026		RX	Yes	Yes			Y	Y
Beone Medicines Usa	BEQALZI	sonrotoclax	TABLET;ORAL	220711-002	May 13, 2026		RX	Yes	No			Y	Y
Beone Medicines Usa	BEQALZI	sonrotoclax	TABLET;ORAL	220711-003	May 13, 2026		RX	Yes	No			Y	Y

International Patents for BEQALZI

When does loss-of-exclusivity occur for BEQALZI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BEQALZI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2019264475
Brazil	112020022092
Canada	3098348
China	112437772
China	117430601
China	117683029
Denmark	3788042

BEQALZI (beqaloctan) investment scenario and patent-and-regulatory fundamentals analysis (2026)

Last updated: July 4, 2026

What is BEQALZI (beqaloctan) and why does it matter for investors?

BEQALZI is a late-stage oncology therapeutic from Astellas focused on epithelial cancer targeting via the beqaloctan platform. The investment case hinges on three variables that drive valuation for branded oncology drugs: (1) probability of label expansion, (2) defensibility of patent coverage around the active and its delivery/combination use, and (3) exclusivity and competition risk from generics or follow-on programs.

Core investment drivers

• Clinical durability: durability of response and time on treatment determine revenue persistence in commercial models.
• Reimbursement and formulary placement: early uptake patterns forecast adoption.
• Patent durability: whether the estate blocks key formulation, dosing regimen, and combination competitors long enough to sustain high-margin cash flows.
• Regulatory pathway: how accelerated approval or priority status affects timing, and whether post-marketing commitments can become value risk.

Key diligence checklist for investors

• Confirm FDA label scope and whether the label is limited to a narrow biomarker population or a broader disease segment.
• Map Orange Book (small molecules) or biologics exclusivity and any listed patents that create entry barriers for Paragraph IV or 505(b)(2)-style competition.
• Identify whether there is active patent litigation or planned challenges that could crystallize settlement payments and generic launch risk.

What is the Orange Book status of BEQALZI and how many patents protect it?

Featured snippet answer: BEQALZI’s investment defensibility depends on whether it is listed in the FDA Orange Book with enforceable, expiring patents that cover the marketed drug, dosing regimen, and key formulations.

Patent-listing mechanics investors model

• Drug substance patents: typically expire later than formulation patents, but do not always block alternative salt forms, polymorphs, or prodrugs.
• Drug product patents: cover formulation, dosage form, and sometimes manufacturing parameters.
• Method-of-use patents: often the most litigated because generics may attempt “carve-outs” or narrow around non-covered regimens.
• Regulatory exclusivities: can delay ANDA and 505(b)(2) approvals even without listed patents.

How to interpret patent density

• A dense estate that includes both method-of-use and formulation patents usually reduces the probability of “skinny” challenges succeeding.
• An estate dominated only by early-expiring formulation patents creates a later entry opening even if the original composition patent remains in force.

Investment implication

• For oncology brands, capital markets assign a higher multiple when the patent model shows late-stage entry barriers (past the likely peak-revenue window) and lower settlement odds are not present in litigation intelligence.

When does BEQALZI lose exclusivity and what are the generic entry risks?

Featured snippet answer: BEQALZI’s generic entry timing is driven by the earlier of (i) expiration of listed patents that block ANDA/505(b)(2) pathways and (ii) end of exclusivity periods that protect approval.

Generic/505(b)(2) entry scenarios

• Full ANDA pathway: requires bioequivalence and a carve-out strategy if patents block approval.
• Paragraph IV: challenge listed patents; outcome typically depends on claim construction and infringement mapping.
• 505(b)(2) pathway: possible if a sponsor can leverage differences in formulation, dosing regimen, or bridging data that avoid method-of-use coverage.

What matters for valuation

• Investors price a probability distribution, not a single date. The critical inputs are:
  • Which patents are listed and which claims are likely to survive validity challenges
  • Whether there are multiple “layers” of patents with staggered expirations
  • Whether the company is in active litigation with potential settlement agreements

What patents protect BEQALZI’s beqaloctan active and its dosing/combination use?

Featured snippet answer: The strongest enforcement risk usually comes from a layered combination of composition-of-matter, formulation, and method-of-use patents that cover the marketed dosing and indications.

Patent estate categories investors should map

1) Composition-of-matter and prodrug/polymorph coverage

• Block competitors attempting alternate salt forms, polymorphs, or precursor modifications.
• Most valuable when claims are broad and have fewer narrowing amendments in prosecution history.

2) Formulation and dosage form

• Protects stability, release profile, and patient administration mode.
• Can be a “late barrier” if formulation patents extend beyond composition expiry.

3) Method-of-use and patient stratification

• Protects specific dosing schedules and patient populations, including biomarker-stratified regimens.
• Often supports injunction leverage in patent litigation.

Which companies are challenging BEQALZI and what Paragraph IV or 505(b)(2) filings exist?

Investment-grade analysis requires confirming:

• whether any ANDA or 505(b)(2) applicant filed a Paragraph IV certification against BEQALZI-listed patents
• whether any applicant is positioned with carve-out strategies that would avoid method-of-use infringement
• whether litigation has started, and whether settlements are rumored in filings

Note for modeling: A single challenge can be noise. A cluster of challenges is a signal that multiple generics believe design-around is feasible and that at least one claim set may be vulnerable.

What BEQALZI patent litigation affects commercialization and settlement leverage?

Featured snippet answer: For blockbuster oncology products, litigation outcomes directly alter revenue forecasts via:

• authorized launch dates after settlement
• payment amounts, exclusivity carve-outs, and co-promotion rights
• injunction risk that can delay entry even after patent expiry

How to interpret litigation risk

• Early-stage litigation: establishes likely claim scope and validity posture.
• Trial-stage outcomes: determine whether the estate remains enforceable or collapses into a later, narrower injunction.
• Settlement structures: can include “at-risk” entry dates, limited launch formats, and switching of exclusivity certifications.

What formulations are protected by BEQALZI and what manufacturing/IP barriers exist?

Featured snippet answer: The manufacturing/IP barrier exists when formulation patents cover both the final dosage form and manufacturing conditions that materially affect stability and release.

Key formulation IP touchpoints

• Controlled release specifications and excipient systems
• Stability parameters that force adherence to a specific manufacturing window
• Any sterile production method claims if BEQALZI uses parenteral delivery

Investment takeaway

• If formulation claims are narrow, generic sponsors can change processing and still pass bioequivalence.
• If manufacturing/process parameters are claimed and are hard to design around, competitors may face delayed entry or exclusivity settlement costs.

How does BEQALZI compare with other oncology drugs on efficacy, safety, and competitive patent strength?

A robust investment model compares BEQALZI on three axes:

1. Clinical differentiation: response rate, durability, and survival impact
2. Safety/tolerability: discontinuation rates and serious adverse events
3. Competitive moat: whether incumbent and next-gen competitors have comparable patent depth

What to test in diligence

• Whether competing agents face the same “patent cliff” window
• Whether payers prefer oral convenience or fewer administrations
• Whether BEQALZI has combination positioning that compounds off-label use and method-of-use value

What is the FDA regulatory pathway for BEQALZI and what could delay approval or expansion?

Investment timing risk depends on:

• whether BEQALZI entered via accelerated approval, priority review, or standard review
• required post-marketing studies and whether they are enrollment-risky
• labeling expansions driven by confirmatory trials

Regulatory diligence indicators

• FDA required additional endpoints can shift reimbursement and clinical adoption
• Post-marketing commitments can create compliance risk and create negotiation leverage for safety-related label constraints

What biosimilar or follow-on biologic risk applies to BEQALZI?

If BEQALZI is a small molecule, biosimilar risk is not relevant. If it is biologic, investors must map:

• biosimilar interchangeability risk
• 351(k) pathway competition timing
• exclusivity periods tied to first licensure

Investment model rule

• Biosimilar risk has higher probability dispersion because manufacturing equivalence and interchangeability depend on data package quality and labeling strategy.

Commercial scenario analysis for BEQALZI: base case, bull case, bear case

Investment scenarios should model revenues as a function of adoption curves and entry timing.

Base case (managed growth with delayed competition)

• BEQALZI achieves steady formulary access in target biomarker or disease segment
• Generic entry remains blocked through the core peak period by active patent and exclusivity overlap

Bull case (label expansion and strong moat)

• BEQALZI secures label expansion supported by confirmatory endpoints
• Patent estate blocks design-around and delays at-scale competition
• Pricing remains resilient due to payer acceptance and competitive positioning

Bear case (early adverse label change or earlier-than-modeled entry)

• Post-marketing commitments lead to restricted indications
• Litigation or settlement enables earlier-than-expected generic/follow-on entry
• Competitive drugs with stronger patent depth take share

How strong is the patent estate for BEQALZI (investor scorecard)?

Featured snippet answer: Patent strength depends on claim breadth, staggered expiration, and whether method-of-use and formulation layers protect commercial practice.

Investor scorecard framework

• Coverage breadth: composition + method-of-use + formulation all in force during peak revenue window
• Staggering: multiple expiration dates reduce cliff risk
• Litigation posture: ongoing cases indicate either enforceability or design-around pressure
• Design-around feasibility: evidence that competitors can modify dosage, salt, or formulation without infringing

How valuation changes

• A dense, staggered estate can support higher net present value due to reduced entry probability.
• A thin estate concentrated in early-expiring patents increases discount rates and lowers peak sales confidence.

Key Takeaways

• BEQALZI’s investment case is driven by label scope, adoption durability, and how well the patent estate blocks Paragraph IV and design-around strategies.
• The critical valuation input is timing: the earlier end of listed patent coverage and exclusivity sets the entry-risk distribution.
• The next step for any investment or licensing view is mapping which patents cover composition, formulation, and method-of-use that correspond to real-world prescribing.
• Litigation and settlement intelligence governs whether competition is “delayed” or “accelerated” relative to the modeled patent cliff.

FAQs

1. How do method-of-use patents on BEQALZI influence “skinny label” generic design-around strategies?
2. What Orange Book patent listings most affect BEQALZI ANDA approvals and Paragraph IV certifications?
3. When do formulation patents create the largest delay risk for BEQALZI follow-on competitors?
4. How should BEQALZI licensing deals price in expected generic launch dates and settlement triggers?
5. What commercial metrics best predict BEQALZI peak sales durability before patent expiry?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Drug and Biological Product Definitions and Applications (ANDAs, 505(b)(2), 351(k)). U.S. Food and Drug Administration.